

The content of this presentation is now available as a peer-reviewed publication. View the full article in *The New England Journal of Medicine*: [10.1056/NEJMoa2514661](https://doi.org/10.1056/NEJMoa2514661)



# Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients with high-risk human epidermal growth factor receptor 2–positive (HER2+) primary breast cancer with residual invasive disease after neoadjuvant therapy: Interim analysis of DESTINY-Breast05

Charles E Geyer Jr,<sup>a,b</sup> Yeon Hee Park, Zhiming Shao, Chiun-Sheng Huang, Carlos Barrios, Jame Abraham, Aleix Prat, Naoki Niikura, Michael Untch, Seock-Ah Im, Wei Li, Huiping Li, Yongsheng Wang, Herui Yao, Sung-Bae Kim, Elton Mathias, Yuta Sato, Wenjing Lu, Hanan Abdel-Monem, Sibylle Loibl

On behalf of the DESTINY-Breast05 investigators

<sup>a</sup>NSABP Foundation, Pittsburgh, PA, USA

<sup>b</sup>University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA

Saturday, October 18, 2025  
Presentation LBA1

